A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers

NCT04761744 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

DDR Gene Mutation
Metastatic Solid Tumor

Interventions

DRUG: Nivolumab

Sponsor

Korean Cancer Study Group